Shire reports total revenues of $3008 million for 2009 News-Medical.net VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... and more » |
RxNews Recap for Friday 02-19-10 BioMedReports (subscription) (blog) VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... and more » |
Excellent Results in a Transformational Year for Shire; Core Product Sales up 25% FOXBusiness VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... |
Excellent Results in a Transformational Year for Shire; Core Product Sales up 25% SYS-CON Media (press release) VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... |
Excellent Results in a Transformational Year for Shire; Core Product Sales up 25% American Chronicle VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... |